Prognostic implications of RAS alterations in diverse malignancies and impact of targeted therapies

RAS alterations are often found in difficult‐to‐treat malignancies and are considered “undruggable.” To better understand the clinical correlates and coaltered genes of RAS alterations, we used targeted next‐generation sequencing (NGS) to analyze 1,937 patients with diverse cancers. Overall, 20.9% of cancers (405/1,937) harbored RAS alterations. Most RAS ‐altered cases had genomic coalterations (95.3%, median: 3, range: 0–51), often involving...